GlassScriptPhysician profile
Stacie R Johnson
NPI 1205212677
$6,535.63
in general payments reported to CMS, 2019-2025
42 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $728 · 2023: $998 · 2024: $2,673 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,336 · Travel and Lodging: $731 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,335.78 |
| Travel and Lodging | $731.48 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,834.10 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Abbvie INC. | $1,100.34 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $394.52 | 2021-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.45 | 2021-2025 | Relistor |
| Boston Scientific Corporation | $228.51 | 2021-2025 | Intracept |
| Forte Bio-Pharma LLC | $208.51 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Lundbeck LLC | $174.24 | 2022-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $160.15 | 2021-2025 | Ztlido |
| Pfizer INC. | $155.09 | 2021-2024 | |
| Tersera Therapeutics LLC | $153.79 | 2024-2025 | Prialt |
| Impel Pharmaceuticals INC. | $139.30 | 2022-2023 | Trudhesa |
| Si-Bone, INC. | $136.71 | 2021-2025 | |
| Biodelivery Sciences International, INC. | $129.81 | 2021 | |
| Lilly USA, LLC | $129.63 | 2021-2024 | Emgality |
| Saluda Medical Americas, INC. | $105.47 | 2024-2025 | Evoke |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $102.70 | 2021-2025 | Eterna, Proclaim |
| Vertex Pharmaceuticals Incorporated | $98.24 | 2024-2025 | |
| Protega Pharmaceutials INC | $95.23 | 2025 | Roxybond |
| Amgen INC. | $83.50 | 2021-2022 | |
| Spr Therapeutics, INC | $81.97 | 2023-2025 | Sprint Pns System |
| Azurity Pharmaceuticals, INC. | $63.05 | 2023-2025 | Horizant, Horizant |
| Averitas Pharma INC. | $59.73 | 2023-2024 | Qutenza |
| Horizon Therapeutics Plc | $59.53 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.69 | 2023-2024 | Ajovy |
| Ipsen Biopharmaceuticals, INC | $47.03 | 2025 | Dysport |
| Mml US, INC. | $45.77 | 2025 | Reactiv8 |
| Pacira Pharmaceuticals Incorporated | $44.40 | 2022-2024 | Zilretta, Iovera, Exparel |
| Bioventus LLC | $30.99 | 2025 | Xcell |
| Biohaven Pharmaceutical Holding Company LTD. | $29.48 | 2022 | |
| Vertos Medical, INC. | $29.08 | 2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $28.59 | 2022-2023 | Intracept |
| Grt US Holding, INC. | $26.86 | 2022 | |
| Merck Sharp & Dohme LLC | $25.78 | 2022 | |
| Arbor Pharmaceuticals, INC. | $25.60 | 2021 | |
| Indivior INC. | $21.24 | 2024 | Sublocade |
| Nalu Medical, INC. | $18.46 | 2024 | Nalu Neurostimulation System |
| Conetic Solutions, INC. | $17.63 | 2024 | |
| Biotronik Nro, INC. | $16.51 | 2025 | Prospera |
| Almatica Pharma LLC | $14.97 | 2022 | |
| Tonix Medicines, INC. | $14.90 | 2025 | Tonmya |
| Allergan, INC. | $11.79 | 2021 | |
| Brainsway USA INC | $10.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.